Currently, detection of BRAF and NRAS mutations in ctDNA has shown significant value in predicting treatment response and outcome in melanoma [63, 65, 77] and the recent inclusion of ctDNA analysis in clinical trials [64] further highlights its imminent implementation in clinical practice. This evidence concerns the gene NRAS and melanoma.